246 results about "Calcitonin" patented technology

A complex is provided for the treatment of neurogenic conditions having the formula:

where R¹ is

M is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium (II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium (II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium (II):transporter ligand.

A compound is provided that has the formula

NH₂CH₂CH₂CH₂C(O)N—R   (I)

where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

Purified enzymatic compositions are provided having alpha-amidating enzymes capable of catalyzing the conversion of a peptidyl compound having a C-terminal glycine residue to a corresponding peptidyl amide having an amino group in place of the C-terminal glycine. The purified compositions have specific activities above 25 mU per mg protein and are sufficiently free of proteases to allow effective catalysis of even peptidyl compounds having L-amino acids. Biologically important alpha-amidated products such as calcitonin and other regulatory hormones are efficiently produced using the alpha-amidation reaction catalyzed by the enzymes. Purification by size exclusion chromatography in combination with strong anion exchange chromatography results in homogeneous enzyme species which are used to prepare antibodies specific for the alpha-amidating enzyme. A gene capable of expressing the alpha-amidating enzyme is ligated into an expression vector and transformed into a host cell capable of expressing the gene.

Solid pharmaceutical compositions suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions provide excellent oral bioavailability of pharmacologically active agents, particularly calcitonin.

The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody.

The invention relates to a chemiluminescence quantitative detection kit for procalcitonin, and a preparation method and detection method thereof. The kit comprises a procalcitonin series standard substance, a magnetic separation reagent (magnetic particle suspension coupled with streptavidin), a first reagent (anti-procalcitonin monoclonal antibody solution containing biotin N-hydroxysuccinimide ester label) and a second reagent (anti-procalcitonin monoclonal antibody solution containing alkaline phosphatase label). The sensitivity of the kit prepared from the magnetic particle suspension coupled with streptavidin, anti-procalcitonin monoclonal antibody solution containing biotin N-hydroxysuccinimide ester label and anti-procalcitonin monoclonal antibody solution containing alkaline phosphatase label is up to 0.008ng/ml; and the kit has the advantages of high accuracy, high precision, no need of prediluting the sample, and wide detection range, and is simple and time-saving to operate.

The present invention relates to methods, monitors and systems measuring lysophosphatidylcholine, its derivatives and/or procalcitonin as well as at least one clinical marker (e.g. temperature or respiration rate) and/or at least one biomarker for the early detection of sepsis in a subject.

The invention relates to the field of fluorescence immunochromatography technique in medical immunology, specifically to a procalcitonin detection kit and a procalcitonin detection method. The detection kit is provided with a test cassette and is characterized in that the test cassette is successively provided with, from bottom to top, a PVC plate, a sample pad, a combination pad, a cellulose nitrate film and a water-absorbing pad, wherein a procalcitonin monoclonal antibody labeled by a rare earth fluorescent microsphere is adsorbed on the combination pad, the rare earth fluorescent microsphere has a diameter of 60 to 120 nm, is doped by rare earth lanthanide, is stable in a ground state and emits fluorescent light with a wavelength in a range of 540 to 600 nm under the action of an excitation light source in a wavelength range of 340 to 380 nm, and the monoclonal antibody is a purified mixed monoclonal antibody and is originated from monoclonal antibody cell strains directed at 2 to 6 different procalcitonin antigen epitopes. The procalcitonin detection kit has the advantages of simple operation, rapid reaction, high sensitivity, strong specificity, etc.

A compound is provided that has the formula

NH₂CH₂CH₂CHR¹C(O)N—R  (I)

where R¹ is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

The invention relates to a reagent for determining procalcitonin and a preparation method of the reagent, in order to provide the reagent which has the characteristic of high accuracy degree, and the provided preparation method has the characteristic of convenience in preparation. The technical scheme is that the reagent for determining procalcitonin comprises the following components: a. a procalcitonin reagent 1, b. a procalcitonin reagent 2, and c. a liquid-type procalcitonin reference calibration item. The preparation method of the reagent for determining procalcitonin comprises the following steps of: (1) uniformly mixing the procalcitonin reagent 1; (2) removing the procalcitonin reagent 2, the removing process specifically comprises the following steps of: a. taking a suspension, b. carrying out reaction on a mixture, c. acquiring a carboxylic latex microsphere suspension, d. regulating the concentration, e. taking the suspension in step (3), and adding into the step (4), f. reacting, g. adding cholamine, and h. carrying out centrifugal treatment; and (3) treating the liquid-type procalcitonin reference calibration product: mixing according to the amount of a formula, and ranking according to the content of the procalcitonin or adding a procalcitonin pure product in the mixed liquid.

The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and/or derivatives thereof, a calicitonin, a parathyroid hormone (PTH), a bone morphogenic protein (BMP), an erythropoietin (EPO), an epidermal growth factor (EGF) or a growth hormone. This invention also relates to methods of using the composite microspheres, and methods of preparing same.

The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient having suffered a stroke or a transient ischemic attack, comprising the determination of the level of at least one marker peptide in said sample said marker peptide selected from the group comprising ANP, AVP, ADM, ET-1, troponin, CRP, calcitonin and hGH or fragments thereof or its precursor or fragments thereof and attributing the level of said at least one marker peptides its precursor or fragments thereof with the prognosis of an outcome or assessing the risk for said patient.

The invention discloses a calcitonin magnetic particle chemiluminescent detection kit and a preparation method. The kit includes: magnetic particles coupled with calcitonin capture antibody, acridinium ester-labeled calcitonin detection antibody, calcitonin calibrator, chemiluminescence pre-excitation solution A, chemiluminescence excitation solution B and cleaning solution. The kit of the invention uses the magnetic separation chemiluminescence technology as the detection means, and simultaneously combines the acridinium ester labeling technology. The direct chemiluminescence method established by the invention has high sensitivity, strong specificity, accuracy and rapidity, short detection time and higher accuracy and repeatability of detection results, and the kit can be applied to various luminescence detection instruments.

The invention discloses an oral solid lipid nano-particle preparation of calcitonin, which is a particle suspension containing 0.01 percent sodium cholate in a water phase, wherein lipid nano-particles comprise an active medicament component and a lipid material forming the particles. Simultaneously, the preparation method comprises the following steps: dissolving or melting a medicament and a carrier in an organic solvent phase together; quickly infusing the organic phase into the water phase stirred at a low temperature to form a lipid nano-particle dispersion liquid; standing, melting and performing high-speed centrifugal separation on the lipid nano-particle dispersion liquid to obtain a nano-particle deposition; and dispersing the deposition to obtain a target oral calcitonin lipid nano-particle dispersion liquid. The oral solid lipid nano-particle preparation uses the lipid material as a structural matrix material, and the oral solid lipid nano-particle preparation of the calcitonin is prepared through reasonable component proportion to prevent the medicament from leaking in an aqueous medium and release the medicament in modes of in vivo esterase degradation and the like, thus the aim that the medicament contained in a nano-carrier can adjust the serum calcium concentration more reasonably and more safely through biomembranes of mammals is achieved.

The invention discloses a chemiluminescent detection kit for procalcitonin and a preparation method thereof. The kit includes: sample diluent, magnetic particles coated with procalcitonin monoclonal antibody, procalcitonin monoclonal antibody labeled with acridinium ester, procalcitonin series standard solution, chemiluminescence excitation solution A, Chemiluminescence excitation solution B, cleaning solution. The kit of the invention combines the chemiluminescent technology with the immunomagnetic particle, and provides a nearly homogeneous reaction system. Compared with the prior art, the kit of the invention has the advantages of high sensitivity, strong specificity, short reaction time and the like.

The invention relates to a surface enhanced Raman scattering technology-based composite material and a preparation method thereof. The composite material comprises microspheres modified with first target molecules on the surfaces and a second component modified with Raman signal molecules and second target molecule-modified polymers on the surface. In a solution containing a substance to be detected, the substance to be detected, the microspheres and the second component are bonded to the second target molecules through the first target molecules so that the composite material which can be easily precipitated through centrifugation is obtained. The invention also discloses the preparation method and a use of the composite material. The composite material can be used for detecting a human prostate-specific antigen (PSA), a human ferrohemoglobin (Hb), a procalcitonin (PCT) or disease markers (such as tumor markers, cardiovascular disease markers, senile dementia markers, mycoplasma and chlamydia), can effectively reduce false positive and false negative effects and has advantages of high sensitivity, simpleness, fastness and low cost.

The invent9ion discloses a procalcitonin monoclonal antibody hybrid tumor 2H4 and monoclonal antibody. The procalcitonin monoclonal antibody hybrid tumor 2H4 is preserved in the China Center for Type Culture Collection at 16, Dec, 2014, and the preservation number is CCTCC NO: C2014232. The monoclonal antibody prepared aiming at procalcitonin compound oligopeptide has high specificity and sensitivity to the procalcitonin protein detection and lays a foundation for the function study and development of the procalcitonin and the research of corresponding diagnostic reagents.